IMUX

Immunic, Inc.

IMUX · CIK 1280776 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income−$97M
20182025
Operating CF−$86M
20182025
Free Cash Flow−$86M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue————————
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.62$-1.00$-2.11$-3.78$-0.81———
EPS (Diluted)$-0.62$-1.00$-2.11$-3.78$-0.81———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.0B$0.0B$0.1B$0.1B$0.1B$0.2B$0.1B$0.0B
Current Assets$0.0B$0.0B$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.1B$0.1B$0.1B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B—
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$-0.0B$0.0B$0.0B$0.1B$0.1B$0.2B$0.1B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$0.0B$-0.0B$-0.0B$-0.0B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.1B$0.0B$0.1B$0.0B$0.1B$0.0B$0.0B
← Companies